Trials / Active Not Recruiting
Active Not RecruitingNCT06031415
Study of GS-0272 in Participants With Rheumatoid Arthritis
A Multicenter, Randomized, Placebo-Controlled Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Multiple Ascending Doses of GS-0272 in Adult Participants With Rheumatoid Arthritis
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA). The primary objectives of this study are to assess the safety and tolerability of multiple ascending doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple doses of GS-0272, in participants with RA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GS-0272 | Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B) |
| DRUG | Placebo | Administered subcutaneously (for Part A) Administered intravenously or subcutaneously (for Part B) |
Timeline
- Start date
- 2023-09-28
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2023-09-11
- Last updated
- 2026-04-01
Locations
24 sites across 5 countries: United States, Georgia, Moldova, South Korea, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06031415. Inclusion in this directory is not an endorsement.